An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
In what could be the beginning of fresh troubles for Ranbaxy Laboratories, which has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a penalty of $500 million, the health ministry in India, too, has decided to initiate a probe.
Dinesh Thakur is now planning to start a new venture to help the industry and the US regulator avoid another Ranbaxy-like episode.
Say heavy penalties for medical errors might raise health care costs and make practitioners too cautious, says Sushmi Dey
Many feel the fear of epidemic outbreak will grow severe in around a month and once the rainy season gets over, reports Sushmi Dey
No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances